CA2650498A1 - Orally disintegrating tablets - Google Patents

Orally disintegrating tablets Download PDF

Info

Publication number
CA2650498A1
CA2650498A1 CA002650498A CA2650498A CA2650498A1 CA 2650498 A1 CA2650498 A1 CA 2650498A1 CA 002650498 A CA002650498 A CA 002650498A CA 2650498 A CA2650498 A CA 2650498A CA 2650498 A1 CA2650498 A1 CA 2650498A1
Authority
CA
Canada
Prior art keywords
agents
orally disintegrating
directly compressible
hydrochloride
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002650498A
Other languages
English (en)
French (fr)
Inventor
Pratibha S. Pilgaonkar
Maharukh T. Rustomjee
Anilkumar S. Gandhi
Pradnya Bagde
Hetal N. Morvekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rubicon Research Pvt Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2650498A1 publication Critical patent/CA2650498A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002650498A 2006-03-31 2007-03-30 Orally disintegrating tablets Abandoned CA2650498A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN498MU2006 2006-03-31
IN498/MUM/2006 2006-03-31
PCT/IN2007/000138 WO2007113856A2 (en) 2006-03-31 2007-03-30 Directly compressible composite for orally disintegrating tablets

Publications (1)

Publication Number Publication Date
CA2650498A1 true CA2650498A1 (en) 2007-10-11

Family

ID=38562805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002650498A Abandoned CA2650498A1 (en) 2006-03-31 2007-03-30 Orally disintegrating tablets

Country Status (13)

Country Link
US (2) US20090208576A1 (https=)
EP (1) EP2001450B1 (https=)
JP (1) JP5535616B2 (https=)
KR (1) KR101324898B1 (https=)
CN (1) CN101460150B (https=)
AU (1) AU2007232098A1 (https=)
BR (1) BRPI0709909A2 (https=)
CA (1) CA2650498A1 (https=)
IL (1) IL194355A0 (https=)
MX (1) MX2008012299A (https=)
NO (1) NO20084612L (https=)
NZ (1) NZ572106A (https=)
WO (1) WO2007113856A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN101460150B (zh) 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
HUP0700485A3 (en) * 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone
EP2205213A2 (en) 2007-10-01 2010-07-14 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009084017A2 (en) * 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride
ES2393640T3 (es) * 2008-02-13 2012-12-26 Dainippon Sumitomo Pharma Co., Ltd. Comprimidos bucodisgregables
KR101075556B1 (ko) * 2008-11-21 2011-10-20 씨제이제일제당 (주) 구강내 속붕해정 및 그 제조방법
EP2198857A1 (en) 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
PL2398468T3 (pl) 2009-02-17 2017-06-30 Krka, D.D., Novo Mesto Kompozycje farmaceutyczne zawierające zasadę prasugrelu lub jej farmaceutycznie dopuszczalne kwasowe sole addycyjne i sposoby ich otrzymywania
WO2010106936A1 (ja) * 2009-03-16 2010-09-23 ニプロ株式会社 口腔内崩壊錠
GB2495563B (en) * 2009-04-28 2014-12-03 Isp Investments Inc Co-processed excipient compositions
CN102458475B (zh) 2009-05-20 2016-03-30 大日本住友制药株式会社 压制包衣的口腔崩解片
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011001214A1 (en) * 2009-06-30 2011-01-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Surface amorphization of phenprobamate
ES2467141T3 (es) * 2009-07-10 2014-06-12 Merck Patent Gmbh Composición para la fabricación de comprimidos y procedimiento para su preparación
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EA201200485A1 (ru) * 2009-09-15 2012-10-30 Рациофарм Гмбх Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2316434A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of memantine
CN102218040A (zh) * 2010-04-13 2011-10-19 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
EP2384742A1 (en) 2010-05-03 2011-11-09 The Jordanian Pharmaceutical Manufacturing Co. Pharmaceutical excipient, method for its preparation and use thereof
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
US20110300216A1 (en) * 2010-06-03 2011-12-08 First Eric R Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
EP2602255B1 (en) * 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
EP2627323A4 (en) 2010-10-12 2014-03-12 Univ Johns Hopkins HUSTENSTILLENDE COMPOSITIONS WITH MEMANTINE
EP2468254A1 (en) * 2010-12-15 2012-06-27 Hexal AG Orally disintegrating tablet having a taste masking effect
WO2013019056A1 (en) * 2011-08-01 2013-02-07 Sam-A Pharm. Co., Ltd. Novel granule formulation containing sildenafil or pharmaceutically acceptable salts thereof as an active ingredient
WO2013072932A2 (en) 2011-09-30 2013-05-23 Rubicon Research Private Limited Oral care compositions
WO2013058721A1 (en) * 2011-10-13 2013-04-25 Mahmut Bilgic Pharmaceutical granules and production method
CN102525978B (zh) * 2012-02-07 2013-08-07 海南卫康制药(潜山)有限公司 小儿阿莫西林克拉维酸钾组合物
BR112014020434B1 (pt) * 2012-02-22 2021-10-13 Fujifilm Toyama Chemical Co., Ltd. Composição farmacêutica sólida
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
CN102631331A (zh) * 2012-04-26 2012-08-15 北京哈三联科技股份有限公司 奥氮平口腔崩解片制剂及其制备方法
US20150104512A1 (en) * 2012-04-27 2015-04-16 Merck Patent Gmbh Coated tablets and the production thereof
CN103385859A (zh) * 2012-05-08 2013-11-13 中国人民解放军成都军区总医院 一种治疗创伤后应激障碍症的盐酸普萘洛尔口腔崩解片及其制备方法
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
WO2014007775A1 (en) * 2012-07-02 2014-01-09 Mahmut Bilgic A novel formulation having fast dissolution
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
FR2999432B1 (fr) 2012-12-17 2014-12-12 Ethypharm Sa Comprimes orodispersibles obtenus par compression moulage
CN103127024B (zh) * 2013-03-12 2014-10-15 成都天台山制药有限公司 稳定的三磷酸腺苷二钠片剂
CA2906029C (en) * 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
GR1008186B (el) * 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
BR112015030140A2 (pt) * 2013-06-03 2017-07-25 Mcneil Ab forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
WO2015008825A1 (ja) 2013-07-19 2015-01-22 株式会社三和化学研究所 口腔内崩壊錠
KR101428018B1 (ko) * 2013-10-18 2014-08-12 주식회사 한독 아리피프라졸 함유 구강 붕해 정제 및 이의 제조 방법
WO2015072602A1 (ko) * 2013-11-15 2015-05-21 (주)다미화학 난용성 물질의 수용액 가용화 조성물 및 이를 이용한 난용성 물질의 수용액 가용방법
US20150157660A1 (en) * 2013-12-10 2015-06-11 Lifewave, Inc. Nutritional product composition for energy
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN104027319A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 一种塞来昔布分散片及其制备方法
JP2017532301A (ja) * 2014-09-24 2017-11-02 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法
CN104490832A (zh) * 2014-12-05 2015-04-08 海南卫康制药(潜山)有限公司 一种华法林组合物冻干片及其制备方法
EP3247403A1 (de) 2015-01-22 2017-11-29 Pfeifer & Langen GmbH & Co. KG Cellobiose in zusammensetzungen zum verzehr oder zur einnahme
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN105935445B (zh) * 2016-03-28 2019-02-01 赤峰赛林泰药业有限公司 含2-(-4-异丁基苯基)丙酸右旋物的药物组合物及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201617675A2 (tr) 2016-12-02 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Ari̇pi̇prazole monohi̇drat formülasyonlarinin ağizda dağilan tablet formu
JP6838474B2 (ja) * 2017-04-14 2021-03-03 大正製薬株式会社 固形組成物
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
CN109806232A (zh) * 2017-11-20 2019-05-28 四川科瑞德制药股份有限公司 盐酸替扎尼定口崩片及其制备方法
CN110613691A (zh) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 一种含有peg-dspe-盐酸美金刚复合物的口崩片
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法
PT3682870T (pt) * 2019-01-15 2023-09-25 Dr Willmar Schwabe Gmbh & Co Kg Processo para a preparação de comprimidos fáceis de tomar com extrato seco de folhas de ginkgo biloba
CN109975461B (zh) * 2019-04-10 2022-03-22 中生北控生物科技股份有限公司 维生素d及其代谢物的质谱检测用校准品和质控品及其制备方法和应用
CN111419816A (zh) * 2020-04-28 2020-07-17 广东润源中天生物科技有限公司 一种b族维生素片剂及其生产方法
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
CN111838663A (zh) * 2020-08-05 2020-10-30 田井文 一种食药两用的壮阳补肾中药组合物及其制备方法
JP7846211B2 (ja) * 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
CN113712926A (zh) * 2021-08-31 2021-11-30 南京恒正药物研究院有限公司 一种西地那非口崩片
WO2023088885A1 (en) * 2021-11-16 2023-05-25 Dsm Ip Assets B.V. Granules obtainable by continuous melt granulation
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN115089552B (zh) * 2022-06-10 2024-03-29 南京瑞捷医药科技有限公司 一种布洛芬口腔崩解片
USD1080854S1 (en) * 2022-12-13 2025-06-24 Church & Dwight Co., Inc. Oral product
US20240408042A1 (en) * 2023-06-08 2024-12-12 Clinical Research Associates LLC Orally disintegrating baclofen compositions and methods of making same
MX2023008370A (es) * 2023-07-13 2025-02-10 Posi Visionary Solutions Llp Composicion farmaceutica orodispersable de clonazepam
GB2644313A (en) * 2024-09-27 2026-04-01 Novumgen Ltd An orodispersible tablet of Famotidine and its process of preparation

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4480068A (en) 1981-09-14 1984-10-30 Fiberglas Canada Inc. High temperature resistant binders
US4719181A (en) 1985-12-20 1988-01-12 Warner-Lambert Company Free flowing granular indicator material for peroxidase-like activity
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
ES2097155T3 (es) 1989-10-02 1997-04-01 Cima Labs Inc Forma de dosificacion efervescente y metodo de administracion.
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
DE4439858A1 (de) 1994-11-08 1996-05-09 Merck Patent Gmbh Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung
AU2555997A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19615418A1 (de) 1996-04-22 1997-10-23 Merck Patent Gmbh Polyol-Zusammensetzung
JP3797387B2 (ja) 1996-06-14 2006-07-19 協和醗酵工業株式会社 口腔内速崩壊錠
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
JPH11302157A (ja) 1998-04-17 1999-11-02 Eisai Co Ltd 口腔内速崩壊性錠剤
DE69934505T2 (de) 1998-05-18 2007-10-04 Takeda Pharmaceutical Co. Ltd. Im munde zerfallende tablette enthaltend ein benzimidazole
CA2337015C (en) 1998-07-15 2004-09-07 Asahi Kasei Kogyo Kabushiki Kaisha Excipient
TW585786B (en) 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
JP2000086537A (ja) * 1998-09-11 2000-03-28 Fuji Chem Ind Co Ltd 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
CA2374760A1 (en) 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
JP2004517038A (ja) * 2000-06-30 2004-06-10 ザ、プロクター、エンド、ギャンブル、カンパニー 全身の健康増進
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
KR20030081472A (ko) 2001-03-06 2003-10-17 교와 핫꼬 고교 가부시끼가이샤 구강내 속붕괴성 제제
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
US6610266B2 (en) * 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making
DE10161402A1 (de) 2001-12-13 2003-06-18 Merck Patent Gmbh Verfahren zur Herstellung von direkt tablettierbarem beta-Mannit
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
CA2478101A1 (en) * 2002-03-06 2003-09-12 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablets
US6738873B2 (en) 2002-05-24 2004-05-18 Sun Microsystems, Inc. Memory management system supporting deletion of transient objects
US20060163534A1 (en) 2002-10-08 2006-07-27 Ken Sugimoto Oxygen scavenger composition
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
ATE454132T1 (de) 2003-01-21 2010-01-15 Nippon Shinyaku Co Ltd Rasch in der mundhöhle schmelzende tablette
FR2851734B1 (fr) 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
WO2004082664A1 (en) 2003-03-21 2004-09-30 Ranbaxy Laboratories Limited Water-soluble tablets of metformin
KR100503949B1 (ko) 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
IN2003MU00504A (https=) * 2003-06-05 2005-05-13 Alembic Ltd
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
JP2008500965A (ja) * 2004-03-17 2008-01-17 エムペックス・ファーマシューティカルズ・インコーポレーテッド 細菌の排出ポンプ阻害剤の使用および投与
US20070196475A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising silica materials
JP2006052167A (ja) * 2004-08-11 2006-02-23 Rohto Pharmaceut Co Ltd 錠剤組成物
WO2006035313A1 (en) * 2004-09-29 2006-04-06 Aurobindo Pharma Ltd Solid unit dosage forms of 5-ht1 agonist
EP1681048A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating composition of olanzapine or donepezil
US20090062404A1 (en) 2005-03-24 2009-03-05 Daiichi Sankyo Company, Limited Pharmaceutical composition
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
JP2009506053A (ja) * 2005-08-24 2009-02-12 ワイス 酢酸バゼドキシフェン製剤
WO2007097333A1 (ja) 2006-02-20 2007-08-30 Asahi Breweries, Ltd. 顆粒、錠剤およびそれらの製造方法
CN101460150B (zh) 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
US20070243248A1 (en) 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
AU2007338751A1 (en) 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients

Also Published As

Publication number Publication date
US8545890B2 (en) 2013-10-01
CN101460150A (zh) 2009-06-17
MX2008012299A (es) 2008-11-18
KR20090008307A (ko) 2009-01-21
WO2007113856A3 (en) 2008-06-05
AU2007232098A1 (en) 2007-10-11
IL194355A0 (en) 2009-08-03
WO2007113856A2 (en) 2007-10-11
EP2001450A2 (en) 2008-12-17
JP5535616B2 (ja) 2014-07-02
JP2009532343A (ja) 2009-09-10
BRPI0709909A2 (pt) 2011-07-26
NZ572106A (en) 2010-12-24
CN101460150B (zh) 2014-02-12
EP2001450B1 (en) 2019-01-30
US20090087485A1 (en) 2009-04-02
KR101324898B1 (ko) 2013-11-04
US20090208576A1 (en) 2009-08-20
NO20084612L (no) 2008-10-31

Similar Documents

Publication Publication Date Title
US8545890B2 (en) Orally disintegrating tablets
US20230255891A1 (en) Highly Compactable and Durable Direct Compression Excipients and Excipient Systems
JP6014044B2 (ja) 迅速分散顆粒、口腔内崩壊錠、および方法
US20040265375A1 (en) Orally disintegrating tablets
CN108136032A (zh) 包含糖或糖醇、溶胀型粘合剂、崩解剂及高吸收性赋形剂的复合化造粒物及其制造方法
KR20030094272A (ko) 구강내 급속 붕괴성 정제
JP2009114113A (ja) 口腔内崩壊錠及びその製造方法
KR20080013907A (ko) 드록시도파를 함유하는 안정한 정제
EP2745848B1 (en) Orally disintegrating tablet containing hydroxyalkyl cellulose fine particles
CN1288386A (zh) 崩解剂
JP5572321B2 (ja) 被覆微粒子含有口腔内崩壊錠
Vora et al. Oral dispersible tablet: A popular growing technology
JP5080856B2 (ja) 経口投与用錠剤
TW201113051A (en) Oral disintegrating tablet and manufacturing method thereof
JP2010260803A (ja) キサンタンガム被覆水溶性糖類及び圧縮成形製剤
JP5801266B2 (ja) 疎水性薬物を含む錠剤製造方法
HK1146387A (en) Oral dispersable tablet
HK1166024B (en) Highly compactable and durable direct compression excipients and excipient systems

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160330